These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 1649813

  • 1. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
    Sone S, Kunishige E, Fawzy F, Yanagawa H, Nii A, Maeda K, Atagi S, Heike Y, Nishioka Y, Mizuno K.
    Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
    [Abstract] [Full Text] [Related]

  • 2. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
    Takahashi K, Sone S, Kimura S, Ogura T, Monden Y.
    Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
    [Abstract] [Full Text] [Related]

  • 3. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ, Krco CJ, Wold LE, McKean DJ.
    Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
    Yanagawa H, Sone S, Nii A, Fukuta K, Nakanishi M, Maeda K, Honda M, Ogura T.
    Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
    [Abstract] [Full Text] [Related]

  • 5. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.
    Nii A, Sone S, Utsugi T, Yanagawa H, Ogura T.
    Int J Cancer; 1988 Jan 15; 41(1):33-40. PubMed ID: 2826345
    [Abstract] [Full Text] [Related]

  • 6. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM, Sone S, Inamura N, Ogura T.
    Int J Cancer; 1989 Jul 15; 44(1):170-6. PubMed ID: 2663733
    [Abstract] [Full Text] [Related]

  • 7. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW, Lee JC, Wang RM, Ordonez G, Stone MJ.
    Cancer Res; 1989 Aug 01; 49(15):4103-8. PubMed ID: 2545333
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-12-mediated killer activity in lung cancer patients.
    Haku T, Yanagawa H, Nabioullin R, Takeuchi E, Sone S.
    Cytokine; 1997 Nov 01; 9(11):846-52. PubMed ID: 9367545
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP, Manning LS, Robinson BW.
    Clin Exp Immunol; 1990 Oct 01; 82(1):151-6. PubMed ID: 2208789
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH, Withrow SJ, Johnston MR, Kruse CA.
    Am J Vet Res; 1991 Jul 01; 52(7):1132-6. PubMed ID: 1892269
    [Abstract] [Full Text] [Related]

  • 13. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I, Papamichail M.
    Cancer; 1993 Jul 15; 72(2):491-501. PubMed ID: 8319179
    [Abstract] [Full Text] [Related]

  • 14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD, Economou JS, Shau H, Golub SH.
    J Surg Res; 1993 Nov 15; 55(5):486-92. PubMed ID: 8231167
    [Abstract] [Full Text] [Related]

  • 15. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
    Dunlap NE, Lane VG, Cloud GA, Tilden AB.
    Cancer; 1990 Oct 01; 66(7):1499-504. PubMed ID: 1698527
    [Abstract] [Full Text] [Related]

  • 16. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA, Wright C, Forman SJ.
    Leukemia; 1997 May 01; 11(5):723-8. PubMed ID: 9180298
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
    Basu S, Sodhi A, Singh SM, Suresh A.
    Immunol Lett; 1991 Mar 01; 27(3):199-204. PubMed ID: 2060971
    [Abstract] [Full Text] [Related]

  • 19. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
    Melis M, Spatafora M, Melodia A, Pace E, Gjomarkaj M, Merendino AM, Bonsignore G.
    Eur Respir J; 1996 Sep 01; 9(9):1831-8. PubMed ID: 8880099
    [Abstract] [Full Text] [Related]

  • 20. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y, Watanabe S, Kodama T.
    Jpn J Clin Oncol; 1987 Jun 01; 17(2):129-39. PubMed ID: 3497285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.